Royalty Pharma (RPD) Stock Overview
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
RPD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Royalty Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.12 |
| 52 Week High | US$39.07 |
| 52 Week Low | US$25.73 |
| Beta | 0.42 |
| 1 Month Change | 10.54% |
| 3 Month Change | 14.22% |
| 1 Year Change | 18.37% |
| 3 Year Change | 6.84% |
| 5 Year Change | n/a |
| Change since IPO | 13.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| RPD | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.4% | -1.3% | 1.9% |
| 1Y | 18.4% | 20.5% | 7.5% |
Return vs Industry: RPD underperformed the German Pharmaceuticals industry which returned 20.5% over the past year.
Return vs Market: RPD exceeded the German Market which returned 7.5% over the past year.
Price Volatility
| RPD volatility | |
|---|---|
| RPD Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 14.0% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: RPD has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: RPD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 100 | Pablo Legorreta | www.royaltypharma.com |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc Fundamentals Summary
| RPD fundamental statistics | |
|---|---|
| Market cap | €22.08b |
| Earnings (TTM) | €654.15m |
| Revenue (TTM) | €2.02b |
Is RPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPD income statement (TTM) | |
|---|---|
| Revenue | US$2.38b |
| Cost of Revenue | -US$295.84m |
| Gross Profit | US$2.67b |
| Other Expenses | US$1.90b |
| Earnings | US$770.95m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.80 |
| Gross Margin | 112.44% |
| Net Profit Margin | 32.42% |
| Debt/Equity Ratio | 92.1% |
How did RPD perform over the long term?
See historical performance and comparisonDividends
Does RPD pay a reliable dividends?
See RPD dividend history and benchmarks| Royalty Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Feb 20 2026 |
| Dividend Pay Date | Mar 10 2026 |
| Days until Ex dividend | 4 days |
| Days until Dividend pay date | 14 days |
Does RPD pay a reliable dividends?
See RPD dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/22 14:52 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Royalty Pharma plc is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Geoffrey Meacham | Citigroup Inc |
| Prem Chulaki | CrispIdea |